Cambridge, Massachusetts Thursday, October 17, 2024, 17:00 Hrs [IST] ...

有趣的是，Cullinan的股票显示出显著的动力，InvestingPro提示强调过去一年的价格回报率为95.23%。这一大幅增长表明市场对该公司的产品线（包括最近获FDA批准的CLN-978项目）持乐观态度。此外，该公司的资产负债表上现金多于债务，这可能为其推进临床试验提供财务灵活性。

该公司还获得澳大利亚人类研究伦理委员会批准,开始针对治疗系统性红斑狼疮 (SLE)的药物CLN-978的全球一期试验。尽管Morgan Stanley将Cullinan的目标价下调至38美元,但仍维持了对公司的增持评级。

Cullinan Therapeutics said the U.S. Food and Drug Administration approved its investigation new drug application for CLN-978, a potential treatment for lupus. The biopharmaceutical company said the ...

Analyst Julian Harrison of BTIG maintained a Buy rating on Cullinan Management (CGEM – Research Report), retaining the price target of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) has received a consensus recommendation of “Buy” from the six ratings firms that are covering the firm, MarketBeat Ratings reports.

Cullinan Therapeutics has filed an investigational new drug application with the U.S. Food and Drug Administration (FDA) for CLN-978 for the treatment of systemic lupus erythematosus (SLE). Continue ...

HC Wainwright & Co.：重申Cullinan Therapeutics(CGEM.US)评级，由买入调整至买入评级, 目标价由28.00美元调整至28.00美元。 Cullinan Oncology（CGEM.US）公司简介 ...

BTIG analyst Julian Harrison reiterated a Buy rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target of ...

CAMBRIDGE, Mass. - Cullinan Therapeutics, Inc. (NASDAQ: CGEM), a biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) to proceed with Phase 1 clinical ...